Although there was no association between heterozygous or homozygous genotypes for the MTHFR A1298C polymorphism and the clinical outcomes of the disease, the results of a further analysis in male patients carrying the mutant C allele demonstrated an increased likelihood of having worse MS progression (OR: 1.66 (1.02–3.43), p < 0.05), a finding that was not observed in female patients (Table 9). This evidence concerns the gene MTHFR and myeloid sarcoma.